ACTRN12621000468820已完成1 期
A Phase 1, Randomised Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of PRTX007 in Normal Healthy Volunteers
Primmune Therapeutics Australia Pty Ltd0 个研究点目标入组 112 人开始时间: 2021年4月20日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 112
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •a. Female participants must be of non-childbearing potential, or,
- •b. If of childbearing potential, be non-pregnant or lactating and agree to use highly effective contraception from screening through 30 days post- dose.
- •c. Male participants, if not surgically sterilized and if engaging in sexual intercourse with a female partner of childbearing potential, must be willing to use highly effective contraception from screening through 90 days post-dose and agree not to donate sperm during this period.
- •3. Is judged to be in good health based on medical history, physical examination, vital sign measurements, and laboratory safety tests performed at the screening visit and/or before the first dose of study drug.
- •4. Weigh at least 45 kg at the time of screening
- •5. Have a body mass index (BMI) between 18.0 and 32.0 kg/m2 at the time of screening
- •6. Negative SARS-CoV2 test per site standards
- •7. Agrees to be available for all study visits and cooperate fully with the requirements of the study protocol, including the schedule of assessments
- •8. Willing to refrain from over-the-counter or prescription medications or herbal, nutritional or dietary supplements from 7 days before first dose through the end of study.
- •9. Willing to refrain from alcohol and caffeine from 48 hours before first dose through the last dose of study drug
- •10. Subjects who smoke no more than 2 cigarettes or equivalent per week can be included in the study but must be willing to abstain from smoking during the confinement period.
- •11. Willing and able to provide written informed consent
排除标准
- •1.. Has an active malignancy, or history of malignancy, excluding basal or squamous cell carcinoma of the skin, within 2 years prior to screening
- •2.. History of cardiovascular, cerebrovascular, or peripheral vascular disease, including, but not limited to, unstable angina, myocardial infarction, congestive heart failure, cardiac arrhythmia, hypertension, hypotension, or tachycardia.
- •3. Has a clinically significant history or presence of electrocardiogram (ECG) findings as judged by the PI or designee at screening
- •4. Has clinically significant laboratory abnormalities
- •5. History of prescription drug abuse or illicit drug use within 6 months prior to screening
- •6. History of alcohol abuse within 5 years prior to screening
- •7. Positive alcohol breath test or urine test for drugs of abuse
- •8. Positive test results for hepatitis B surface antigen, hepatitis B core antibodies, hepatitis C virus antigen, and anti-human immunodeficiency virus (HIV) type 1 antibody
- •9. Has received treatment with another investigational drug, investigational device, or approved therapy for investigational use within 30 days or 5 half-lives (whichever is longer) prior to dosing
- •10. Has donated blood or plasma within 30 days prior to screening, or had a loss of whole blood of more than 500 mL within the 30 days prior to screening, or receipt of a blood transfusion within one year prior to screening
- •11. Has experienced symptoms of acute illness or chronic disease within 14 days prior to screening, or any disease or condition (medical or surgical) that, by the determination of the PI, might compromise interpretation of safety or PK data, or would place the subject at risk as a result of participation in the study
- •12.Is unable to cooperate fully with the requirements of the study protocol, including the schedule of assessments, or likely to be non-compliant with any study requirements
- •13.Other unspecified reasons that, in the opinion of the PI or Sponsor, make the subject unsuitable for enrollment.
研究者
相似试验
已完成
1 期
A Phase 1 Randomised, Double-Blind, Placebo-Controlled, Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of Orally Administered PRN1008Healthy VolunteersInflammatory and Immune System - Autoimmune diseasesACTRN12614000359639Clinical Network Services (CNS) Pty Ltd.108
招募中
1 期
An interventional study to evaluate the safety and immune response of a vaccine against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2, the virus that causes COVID-19 infection) when given to healthy adult participants.COVID-19Infection - Other infectious diseasesACTRN12620000674932niversity of Queensland120
尚未招募
1 期
A Phase 1, Randomized Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Intermittent Consecutive Day Dosing Regimen of PRTX007 in Healthy Adultsassa VirusLassa VirusInfection - Other infectious diseasesACTRN12624000981527nited States Defense Threat Reduction Agency (DTRA)15
已完成
1 期
A Phase I Randomised, Double-Blind, Placebo-Controlled Dose Escalating Study of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Oral NP202 in Adult Healthy VolunteersCardiac remodelling post acute myocardial infarctionCardiovascular - Other cardiovascular diseasesACTRN12614000479606euProtect Pty Ltd64
尚未招募
不适用
A Safety and Tolerability study of the drug UE2343, a potential treatment for Alzheimer's Disease and Mild Cognitive Impairment.DementiaAlzheimer's diseaseACTRN12615000117516Actinogen Medical24